« Back
Application of metabolomics in drug-resistant epilepsy research
Poster Title: Application of metabolomics in drug-resistant epilepsy research
Submitted on 07 Dec 2015
Author(s): Federica Murgia1, Simone Poddighe1, Francesco Del Carratore1, Lorenzo Polizzi2, Antonella Muroni2, Luigi Barberini3, Monica Puligheddu3, Francesco Marrosu2 , Luigi Atzori1
Affiliations: 1 Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. 2 Department of Medical Sciences, 3 Department of Public Health, Clinical and molecular medicine
This poster was presented at Metabomeeting 2015
Poster Views: 2,673
View poster »

Poster Information
Abstract: Introduction: Drug resistance is a critical issue in the treatment of epileptic patients. One third of people with epilepsy are resistant to old and new antiepileptic drugs. Metabolomics could provide a tool to investigate possible markers of drug resistance in a population of epileptic subjects suggesting also a possible mechanism. Materials and methods: Blood samples were collected from 3 groups: 1) healthy patients (n=35); 2) patients “responder” (R) to the drug therapy (n=18), and 3) patients “not responder” (NR) (n=17). The samples were analysed by using a Varian UNITY INOVA 500 spectrometer. Multivariate statistical analysis was performed by using SIMCA-P+ software. The metabolites corresponding to the discriminant variables were identified and quantified by using Chenomx software. Results: A different metabolic profile was identified for the three different groups. In particular, the group of the pathological patients were characterized by an increase of acetate, acetoacetate, acetone and scyllo-inositol compared to controls group, and a decrease in lactate, glucose and citrate. The metabolic fingerprint of the class of NR was significantly different from R based on increased levels of ketone bodies. Conclusions: Metabolomics represents an important tool for biomarker discovery in drug-resistant epilepsy and for the study of the pathophysiology of this disease.Summary: Metabolomics represents an important tool for biomarker discovery in drug-resistant epilepsy and for the study of the pathophysiology of this disease.References: 1) Pati S. and Alexopoulos AV, Pharmacoresistant epilepsy: From pathogenesis to current and emerging terapies, Cleve Clin J Med 2010; 77:7457-467.
2) Sinclair AJ, Viant MR, Ball AK, et al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-a diagnostic tool? NMR Biomed. 2010;23(2):123-32.
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

4D Lipidomics workflow utilizing PASEF acquisition mode for increased throughput
Florian Zubeil 1 , Ansgar Korf 1 , Viola Jeck 1 , Aiko Barsch 1 , Nikolas Kessler 1 , Sven W. Meyer 1

Non-targeted metabolomics ID workflows providing custom annotation confidence reporting: CCS-enabled annotation workflows
Aiko Barsch1; Matthias Szesny1; Ulrike Schweiger-Hufnagel1; Sofie Weinkouff1, Nikolas Kessler1

Improved sensitivity and higher lipid annotation ID capabilities using a new vacuum insulated heated ESI source
Matthias Szesny, Lucy Woods, Sven Meyer, Ansgar Korf, Nikolas Kessler, Aiko Barsch

Metabolomics Core Facility provides ready to use data exploration with MetaboScape
Jörg Büscher 1 , Sofie Weinkouff 2 , Ansgar Korf 2 , Aiko Barsch 2 , Nikolas Kessler 2

Lipidomics profiling of plasma samples from patients with SARS CoV 2 by timsTOF Pro 2 PASEF
Jun Yang 1 , Aaron Peng 1 , Xuejun Peng 2 , Lucy Woods 2